A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)

Mark D Wheeler, Margarita Barrientos-Perez, Fu-Sung Lo, Bo Liang, Alison Lunsford, Ólöf Thórisdóttir, Nehama Zuckerman-Levin, Mark D Wheeler, Margarita Barrientos-Perez, Fu-Sung Lo, Bo Liang, Alison Lunsford, Ólöf Thórisdóttir, Nehama Zuckerman-Levin

Abstract

There are limited studies evaluating the safety and efficacy of treatments in young people with type 2 diabetes (T2D). This study compared the efficacy and safety of insulin detemir versus neutral protamine Hagedorn (NPH) insulin, both in combination with metformin and lifestyle intervention, in children and adolescents with T2D. This randomized, open-label, phase 3 trial recruited patients (n = 42) aged 10-17 years diagnosed with T2D already receiving metformin ± other oral antidiabetic drugs ± basal insulin. Patients were randomized (1:1) to receive either insulin detemir or NPH insulin, both with the maximum tolerated dose of metformin, and lifestyle intervention, over 26 weeks. Enrollment terminated prematurely after 17 months due to a very slow recruitment rate (12% of the target met). After 26 weeks, the observed mean HbA1c value had decreased by 0.61% points in the insulin detemir group vs. 0.84% points in the NPH insulin group. The rate of symptomatic blood glucose-confirmed hypoglycemic episodes was 0.4 episodes/patient-year of exposure (PYE) for insulin detemir vs. 1.1 episodes/PYE for NPH insulin.

Conclusion: No safety issues were revealed with either basal insulin. Due to the low number of patients recruited, no efficacy conclusions could be drawn. ClinicalTrials.gov identifier: NCT02131272. What is known: • There is a growing worldwide epidemic of type 2 diabetes in children and adolescents. • There is a lack of research and limited treatment options currently available in this population. What is new: • No safety issues with insulin detemir or neutral protamine Hagedorn insulin in children and adolescents with type 2 diabetes were observed. • Improving clinical trial recruitment, along with providing early, efficacious, and safe treatment options, in this population is critical.

Keywords: Adolescents; Children; Insulin detemir; NPH insulin; Type 2 diabetes.

Conflict of interest statement

Conflict of interest

BL and OT are employees of Novo Nordisk. The remaining authors have no conflicts of interest to declare.

Informed consent

Written informed consent was collected from all patients or legally acceptable representatives.

Figures

Fig. 1
Fig. 1
a Mean change in HbA1c over time, and individual patient plots for HbA1c over time in b insulin detemir and c NPH insulin groups by week of treatment. NPH neutral protamine Hagedorn

References

    1. American Diabetes Association (2017) Standards of medical care in diabetes-2018: summary of revisions. Diabetes Care 41:S1–S159
    1. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, Bell R, Badaru A, Talton JW, Crume T, Liese AD, Merchant AT, Lawrence JM, Reynolds K, Dolan L, Liu LL, Hamman RF, SEARCH for Diabetes in Youth Study Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311:1778–1786. doi: 10.1001/jama.2014.3201.
    1. Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, Silink M, Donaghue KC. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29:1300–1306. doi: 10.2337/dc05-2470.
    1. Fazeli Farsani S, van der Aa MP, van der Vorst MMJ, Knibbe CAJ, de Boer A. Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches. Diabetologia. 2013;56:1471–1488. doi: 10.1007/s00125-013-2915-z.
    1. Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab. 2013;15:978–986. doi: 10.1111/dom.12106.
    1. Gemmill JAL, Brown RJ, Nandagopal R, Rodriguez LM, Rother KI. Clinical trials in youth with type 2 diabetes. Pediatr Diabetes. 2011;12:50–57. doi: 10.1111/j.1399-5448.2010.00657.x.
    1. Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci. 2015;1353(1):113–137. doi: 10.1111/nyas.12939.
    1. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–1274. doi: 10.2337/dc05-1365.
    1. Imperatore G, Boyle JP, Thompson TJ, SEARCH for Diabetes in Youth Study Group et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care. 2012;35:2515–2520. doi: 10.2337/dc12-0669.
    1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19. doi: 10.1007/s00125-002-1009-0.
    1. Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017;11:3–12. doi: 10.1016/j.pcd.2016.09.003.
    1. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11. 2002;2002:1–190.
    1. Lawrence JM, Imperatore G, Dabelea D, SEARCH for Diabetes in Youth Study Group et al. Trends in incidence of type 1 diabetes among non-Hispanic white youth in the U.S., 2002–2009. Diabetes. 2014;63:3938–3945. doi: 10.2337/db13-1891.
    1. Ludvigsson J. Prevention of adverse events in juvenile diabetes. Minerva Pediatr. 2004;56:277–290.
    1. Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, Imperatore G, Linder B, Marcovina S, Pettitt DJ, Pihoker C, Saydah S, Wagenknecht L, SEARCH for Diabetes in Youth Study Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017;376:1419–1429. doi: 10.1056/NEJMoa1610187.
    1. Nadeau KJ, Anderson BJ, Berg EG, Chiang JL, Chou H, Copeland KC, Hannon TS, Huang TTK, Lynch JL, Powell J, Sellers E, Tamborlane WV, Zeitler P. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care. 2016;39:1635–1642. doi: 10.2337/dc16-1066.
    1. Nguyen TT, Jayadeva V, Cizza G, Brown RJ, Nandagopal R, Rodriguez LM, Rother KI. Challenging recruitment of youth with type 2 diabetes into clinical trials. J Adolesc Health. 2014;54:247–254. doi: 10.1016/j.jadohealth.2013.08.017.
    1. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007;369:1823–1831. doi: 10.1016/S0140-6736(07)60821-6.
    1. Reinehr T, Schober E, Roth CL, Wiegand S, Holl R, DPV-Wiss Study Group Type 2 diabetes in children and adolescents in a 2-year follow-up: insufficient adherence to diabetes centers. Horm Res. 2008;69:107–113.
    1. Strandberg AY, Khanfir H, Mäkimattila S, Saukkonen T, Strandberg TE, Hoti F. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults. Ann Med. 2017;49:357–364. doi: 10.1080/07853890.2016.1278302.
    1. Tamborlane WV, Klingensmith G. Crisis in care: limited treatment options for type 2 diabetes in adolescents and youth. Diabetes Care. 2013;36:1777–1778. doi: 10.2337/dc13-0743.
    1. Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, Silverstein J, Tumini S, Ocampo Francisco AM, Kinduryte O, Danne T. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2015;16:164–176. doi: 10.1111/pedi.12263.
    1. TODAY Study Group Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. Int J Obes. 2010;34:217–226. doi: 10.1038/ijo.2009.195.
    1. TODAY Study Group Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. Diabetes Care. 2013;36:1749–1757. doi: 10.2337/dc12-2393.
    1. TODAY Study Group. Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–2256. doi: 10.1056/NEJMoa1109333.
    1. Young TK, Dean HJ, Flett B, Wood-Steiman P. Childhood obesity in a population at high risk for type 2 diabetes. J Pediatr. 2000;136:365–369. doi: 10.1067/mpd.2000.103504.
    1. Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, Maahs D, International Society for Pediatric and Adolescent Diabetes Type 2 diabetes in the child and adolescent. Pediatr Diabetes. 2014;15(Suppl. 20):26–46. doi: 10.1111/pedi.12179.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner